Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and Decitabine in AML
NCT02093403Phase 1Completed
- Start
- Mar 2014
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in acute myeloid leukemia (AML). Primary endpoints: Maximum Tolerated Dose at 31 days, Incidence of severe (grade 3+) adverse events or toxicities up to 3 years and 2 more. Started Mar 2014; status: completed.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02093403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02093403.